cas 1581304-46-2|| where to buy 3,5-dichloro-4-[(6-chloropyridazin-3-yl)oxy]aniline

Nom du produit:3,5-dichloro-4-[(6-chloropyridazin-3-yl)oxy]aniline

IUPAC Name:3,5-dichloro-4-[(6-chloropyridazin-3-yl)oxy]aniline

: CAS：1581304-46-2; Formule moléculaire：C10H6Cl3N3O; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1581304-46-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1581304-46-2; Formule moléculaire:C10H6Cl3N3O; Point de fusion:-; Code SMILES:NC1=CC(Cl)=C(OC2=CC=C(Cl)N=N2)C(Cl)=C1; Densité:

: Numéro de catalogue:CM1044504; Poids moléculaire:290.53; Point d'ébullition:; N° Mdl:; Stockage:

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Resmetirom; Sept. 13, 2023, Madrigal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis.
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD).
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis. Resmetirom is the only orally administered, small-molecule, liver-directed, truly β-selective THR agonist in Phase 3 development.